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Abstract In 1989, we demonstrated for the first time the expres- 
sion of the VDAC 'Porin 31HL' in the plasmalemma of human 
B lymphocytes, then giving first evidence of a multi-topological 
expression of VDAC. Meanwhile, data from this and other labo- 
ratories support our proposal of a multi-compartment distribution 
of the channel in mammalian tissues. Here, by biotinylation of 
plasmalemma-integrated proteins of proven living B lymphocytes, 
followed by two-dimensional electrophoresis, immuno- and strep- 
tavidin affinity blotting, we show that part of the channel mole- 
cules can be labelled at the outer membrane of the cells. Thus, 
by a relevant approach our results invalidate objections concern- 
ing putative cross-reactivity of anti-human Type-1 porin antibod- 
ies with non-VDAC proteins at the outer cell membrane. 
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1. Introduction 
these monoclonal ntibodies on normal human T and B lym- 
phocytes and several other mammalian cells by this and other 
laboratories on the level of light and electron microscopy vali- 
dated the multi-topological expression of Type-1 mammalian 
porin [5,12 17]. Recent data on the co-purification of VDAC 
with the GABAA receptor [18] are in agreement with our obser- 
vation on the expression of VDAC in the plasmalemma. Mi- 
crosequencing of proteins from caveolae of mammalian lung 
epithelium showed the expression Type-1 in this outer cell 
membrane compartment [19]. These data were recently re- 
viewed [20,21]. 
Here, we show by labelling the proteins at the surface of 
proven living B lymphocytes with Sulfo-NHS-Biotin that Type- 
1 human porin is found in the cytoplasmic membranes of the 
cells, Plasmalemma-integrated human porin was detected after 
two-dimensional electrophoresis by immuno- and streptavidin 
affinity-blotting techniques. The data were presented at the 
39th Annual Meeting of the Biophysical Society of the USA in 
San Francisco, CA, February 12-16, 1995. 
In 1989, by cytotoxicity tests and indirect immuno-fluores- 
cence microscopy, we documented the localization of the volt- 
age-dependent anion-selective channel (VDAC) [1,2] 'Porin 
31HL' in the plasmalemma of transformed human B lympho- 
cytes and the accessibility of its N-terminus at the outer cell 
surface. We then applied antisera gainst mature 'Porin 31HL' 
and synthetic peptides of the N-terminal part of the molecule 
[3]. As a basis, we had purified 'Porin 31HL' from crude B 
lymphocyte membranes. Sequence analysis proved the protein 
preparation to be homogeneous and furthermore resulted in 
the first complete primary structure of VDAC in the animal 
kingdom [3,4]. 
Meanwhile, support came from the preparation and charac- 
terization of eight mouse monoclonal nti-'Porin 31HL' anti- 
bodies: all eight monoclonals are directed against the N-termi- 
nal part of the channel molecule [5], they furthermore discrim- 
inate between synthetic peptides of the N-terminal region of 
Type-1 and Type-2 human porin [6-11]. The application of 
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Abbreviations." VDAC, voltage-dependent a ion-selective channel; 
'Porin 31 HL', 31 kDa human lymphocyte porin; NHS, N-hydroxysul- 
fosuccinimide-ester of biotin; NEPHGE, non-equilibrium pH gradient 
gel electrophoresis; SDS-PAGE, sodium-dodecylsulfate poly- 
acrylamide gel electrophoresis; FITC, fluoresceinisothiocyanate; 
PMSF, phenylmethylsulfonylfluoride; EDTA, ethylenediamine- 
tetraacetic acid; PVDF, polyvinylidendifluoride; BSA, bovine serum 
albumine; HRP, horseradish peroxidase. 
2. Materials and methods 
2.1. Cells" 
Acute lymphoblastic leukemia cells (KM3), grown in RPMI 1640 
medium supplemented with 10% fetal calf serum were washed 2times 
in phosphate-buffered saline (PBS: 0.137 M NaC1, 0.002 M KCI, 0.008 
M Na2HPO4, 0.008 M KH2HPO4, pH 7.4) and resuspended at 108/ml 
in PBS. Light microscopy with Trypan blue exclusion was used to 
control viability of the cells before biotinylation. 
2.2. Biotinylation 
To each ml of cell suspension 200/~l of 20 mM Sulfo-NHS-Biotin 
(Pierce) in PBS, pH 7.4, was added, and pH was adjusted immediately 
to 7.4 with Na2HPO 4(0.008 M Na2HPO 4, 0.137 M NaCI, 0.002 M KC1, 
pH 9.0). The reaction was allowed to proceed for 30 min at 4°C with 
slow rotation, afterwards cells were washed 3times with PBS [22-25]. 
To control labelling results and the viability of the cells, a 100/zl aliquot 
was incubated for 30 rain at room temperature with 25 ,ug streptavidin- 
FITC-conjugated (Pierce) as a specific ligand to visualize biotin. After 
washing 3times in PBS, the cells were xamined by fluorescence micros- 
copy at 540 rim. 
2.3. Solubilization 
Each ml of labelled cell suspension, containing 108 cells, was solubil- 
ized with NP40 containing buffer (1% NP40, 1 mM EDTA, 50 mM 
NaCI, pH 8.0) and 10 ~1 PMSF protease inhibitor per ml. Suspension 
was gently mixed for 30 min at 4°C, and lysed cells were centrifuged 
at 200 x g for 10 min to remove cell debris. The supernatant was then 
ultracentrifuged at 100,000 x g for 30 min at 4°C and the finally result- 
ing supernatant was retained for further analysis. 
2.4. Electrophoresis 
Proteins were separated by two-dimensional electrophoresis [26,27] 
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according to isoelectric point by NEPHGE in the first dimension, and 
according to molecular weight by SDS-PAGE in the second imension. 
Protein precipitate from 100/ll biotinylated solubilized cells (10 7 
cells) was dissolved in 40/~1 lysis buffer and loaded to NEPHGE gel 
tube (8 M urea, 2% NP40, ampholines 3.5-10) after short incubation 
at 80°C. First dimension was run for 6 h at 400 V. NEPHGE gel was 
equilibrated 2 × 30 min in SDS-PAGE sample buffer for the second 
dimension and loaded to 12% Laemmli gel for SDS-PAGE, which was 
run for 4 h at 40 mA. 
2.5. Western transfer 
SDS-PAGE gel from the second dimension was blotted onto two 
PVDF membranes (Millipore) simultaneously. They were marked by 
pricking with a needle through both membranes in a definite pattern 
to make sure, that they later could be aligned upon another exactly in 
the same position they had during blotting procedure. Western transfer 
was performed in a semidry system between horizontal graphite lec- 
trodes (Biometra) with a discontinuous buffer system for 40 rain at 
1 mA/cm 2gel. After the blotting procedure reversible Ponceau-S staining 
was used to control protein transfer and the membranes were blocked 
at room temperature with Tris-buffered saline (TBS: 0.025 M Tris, 0.15 
M NaCI, pH 7.4) containing 3% BSA and 0.01% sodium azide. 
2.6. Protein vL~ualization 
After washing 3 times in TBS each membrane underwent a different 
procedure for specific protein visualization. At the first membrane the 
high affinity of biotin to its specific non-covalent ligand streptavidin (Kd 
10 '5 M ~) was used to detect the biotinylated proteins of the preparation. 
The membrane was incubated with streptavidin-HRP-conjugated 
(Pierce) 1 : 1000 in TBS for 1 h at room temperature, washed 3 times 
with TBS and developed with chloronaphthol and HzO 2 as substrates 
for the peroxidase nzyme reaction. At the second membrane the spe- 
cific binding of monoclonal mouse immunoglobulins against human 
Type-I 'Porin 31HL' [5,6] (four of them available by Calbiochem- 
Novabiochem Gmbh) was used to detect he Type-1 porin molecules 
of the preparation. The antibodies recognize the acetylated N-terminus 
(11 amino acids) and discriminate Type-1 from Type-2 porin [5,6,7]. 
The membrane was incubated for one hour with 1 : 500 antibodyfrBS 
solution containing 1% BSA, 0.01% sodium azide. After washing in 
TBS, secondary rabbit anti-mouse antibodies, diluted 1:350 in TBS, 
0.01% sodium azide, were coupled to primary antibodies for one hour. 
HRP reaction was visualized with chloronaphthol/H202 in TBS. 
2. 7. Detection of biotinylated Type-1 porin 
After visualization of protein patterns the membranes were screened 
for protein spots which have exactly the same position on each mem- 
brane, i.e. they react with streptavidin as well as with mouse anti-human 
porin antibodies. To find the positions, where these spots overlap, the 
membranes were scanned into a computer, printed onto transparent 
foils and aligned upon one another. The pattern, which was pricked 
through the membranes before Western transfer was used for exact 
alignment. 
3. Results 
The fluorescence microscopy examination of the strep- 
tavidin-FITC incubated, biotinylated cells showed complete 
biotin labeling (Fig. 1). The samples showed no background 
fluorescence, thus there was good contrast o identify specific 
biotin binding. Biotin labelled sites were seen in a continuously 
Fig. 1. Fluorescence light micrograph to control biotin labelling. Biotinylated cells were incubated with streptavidin-FITC to visualize the biotin 
labelling pattern. Notice the continuous labelling pattern and the high viability of cells. (A) Dead cell. 
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Fig. 2. Printed scan of a streptavidin affinity blot. 'Porin 31HL' was biotinylated at the plasmalemma of human B lymphocytes as visualized by 
streptavidin-HRP after Western transfer• Notice the two spots at 31 kDa and IEP 7.8 (Bt) and 7.3 (Ct). 
fluorescing, thin layer at the outer plasma membrane. The 
biotin-ester cannot permeate the membrane of living cells. Only 
few cells, which were not viable enough to exclude the biotin- 
ester, showed intensive fluorescence of the whole cell body, 
which indicates biotin labeling of intracellular proteins. We did 
three experiments, the number of cells showing biotin penetra- 
tion in any case was less than 4/100. 
Evaluating each run, electrophoresis in the first dimension 
showed good separation of reference pI marker proteins. The 
NEPHGE gels built up stable pH gradients within the range of 
4.5-9.0. After second dimension and Western transfer the 
streptavidin-HRP treated membranes howed good protein 
separation according to isoelectric point (IEP) as well as molec- 
ular weight (Fig. 2). The mouse anti-Type-1 human porin anti- 
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Fig. 3. Printed scan of a mouse anti-Type-1 human porin immunoblot. The second membrane, onto which two-dimensionally seperated proteins of 
biotin-labelled cells were simultaneously blotted, was treated with monoclonal mouse anti-human porin antibodies. It shows one more spot at 31 
kDa and IEP 8.1 (A), which cannot be seen at the streptavidin blot (Fig. 2). 
IEP 
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Fig. 4. Synopsis of Figs. 2 and 3. The membranes were transparently printed and aligned upon another. The spots Bt and C~ from the streptavidin 
blot (Fig. 2) show overlapping (Bl/2, C]/2) with B2 and C2 from the anti-human porin blot (Fig. 3). 
body treated second membranes showed the characteristic two- 
dimensional pattern for 'Porin 31HL' (Fig. 3). The anti-Type-1 
VDAC antibody labelled protein spots were at the molecular 
weight of 31 kDa and extended over a pH range of 7.3-8.1 (Fig. 
3; A, B2, C2), as expected for mammalian porin [4,28], indicating 
that the antigen-antibody reaction is not influenced by biotinyl- 
ation. The antibody labelled human porin spots, showing no 
biotinylation at the streptavidin treated membrane, i.e. intracel- 
lular porin, were at the more basic IEP (Fig. 3; A). The two 
biotinylated spots were seen at the more acid isoelectric points 
as expected by forming of biotin-esters with NH2-residues (Fig. 
2; B~, C]; Fig. 3; B2, C3). 
The computer-scanned and transparently printed mem- 
branes howed two spots which were exactly at the same posi- 
tion on each membrane in the aligned foils (Fig. 4; B~/2, C,/2), 
representing spots that react with streptavidin-HRP as well as 
with mouse anti-human-porin a tibodies. One of the three anti- 
Type-1 human porin antibody labelled spots, lying at basic IEP 
(Fig. 3; A) was not seen at the streptavidin blot (Fig. 2), thus 
it was not biotinylated. 
4. Discussion 
By two-dimensional electrophoresis weshow that part of the 
Type-1 VDAC 'Porin 31HL' of highly viable human B lympho- 
cytes can be biotinylated at the outer surface of these cells. This 
proves that the channel is expressed in their plasmalemma. The 
procedure of biotinylation ensures that proteins, identified at 
Western blot membranes by streptavidin, are outer cell mem- 
brane integrated. Thus, spots reacting with streptavidin as well 
as with monoclonal anti-Type-1 human porin antibodies [5,6] 
represent plasmalemma-integrated Type-1 VDAC. Contamina- 
tion by biotinylated proteins from inside of subvital cells, which 
were less than 4% in our preparations, is rather unlikely to 
cause the reaction at the streptavidin membrane. Densitometric 
scanning of the anti-Type-1 human porin treated membrane 
showed, that the two spots which can also be seen at the strep- 
tavidin membrane are actually more than 20% of the total 
VDAC detected (data not shown). However, it has to be men- 
tioned that the spots at the membrane labelled by anti-human 
porin antibodies cannot be compared irectly to those at the 
streptavidin membrane to give quantitative r lations: first, the 
proteins after two-dimensional electrophoresis were blotted si- 
multaneously onto two membranes; econd, detection systems 
with different affinities and sensitivities were afterwards applied 
to each of the blotting membranes. 
In addition we analyzed glycoprotein vesicles of B lympho- 
cytes purified by lectin affinity chromatography which support 
our biotinylation data. Here, in relation to whole cell and crude 
membrane fractions this preparation shows significant enrich- 
ment of plasma membrane VDAC. Simultaneously, there is an 
enrichment of plasmalemma-integrated HLA-DR molecules in 
the vesicle preparation (Reymann, in preparation). Corre- 
spondingly, microsequencing of proteins of caveolin-rich 
plasma membrane vesicles from lung epithelium revealed Type- 
1 porin in those plasma membrane domains [19]. These results 
are in agreement with immunocytochemical d ta on the multi- 
compartment expression of mammalian VDAC given by this 
and other laboratories [3,5,12 17]. Furthermore, co-purifica- 
tion studies of VDAC with the outer cell membrane integrated 
GABAA receptor [18] support our proposal of the multi-topo- 
logical expression of VDAC, recently reviewed [20,21]. 
As a consequence, the paradigm that VDAC is expressed 
only in outer mitochondrial membranes [1,2] has to be modi- 
fied. Furthermore, the ideas concerning function and modula- 
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tion of the channel molecule [8 11] have to be re-estimated. The 
channel characteristics, highly purified VDAC shows after in- 
corporation into black membranes, have to be seen in context 
with its plasmalemmal expression. The channel properties of 
incorporated VDAC are in good agreement with electrophysi- 
ological phenomena at the outer cell membrane, which have up 
to now no known molecular basis [20,21]. 
Acknowledgments: We gratefully acknowledge the support of Elke 
Nyakatura, Gabriele Paetzold and Johann Seehusen, for supplying us 
with cultured cells whenever they were needed. Heidi Winkelbach gave 
skilful support concerning biochemical labortory work. We thank 
Rudolf Borchard and Klaus Wertheim for their practical support in 
construction and realization of special equipment. We are grateful to 
Reiner Schubert, Jan Ficner, Joachim Horn, and Rolf Merker for 
photography and graphical work. 
References 
[1] Schein, St.J., Colymbini, M. and Finkelstein, A. (1976) J. Membr. 
Biol. 30, 99 120. 
[2] Colombini, M. (1979) Nature 279, 643-645. 
[3] Thinnes, F.P., G6tz, H., Kayser, H., Benz, R., Schmidt, W.E., 
Kratzin, H.D. and Hilschmann, N. (1989) Biol. Chem. Hoppe- 
Seyler 370, 1253-1264. 
[4] Kayser, H., Kratzin, H.D., Thinnes, F.P., G6tz, H., Schmidt, 
W.E., Eckart, K. and Hilschmann, N. (1989) Biol. Chem. Hoppe- 
Seyler 370, 1265-1278. 
[5] Babel, D., Walter, G., G6tz, H., Thinnes, F.P., J/irgens, L., K6nig, 
U. and Hilschmann, N. (1991) Biol. Chem. Hoppe-Seyler 372, 
1027-1034. 
[6] Winkelbach, H., Walter, G., Morys-Wortmann, C. Paetzold, G., 
Hesse, D., Zimmermann, B., Fl6rke, H., Reymann, S., 
Stadtmfiller, U., Thinnes, F.P. and Hilschmann, N. (1994) Bio- 
chem. Med. Metab. Biol. 52, 120-127. 
[7] Blachly-Dyson, E., Zambronicz, E.B., Yu, W.H., Adams, V., Mc- 
Cabe, E.R.B., Adelman, J., Colymbini, M. and Forte, M. (1993) 
J. Biol. Chem. 268, 1835-1841. 
[8] Mannella, C.A. (1992) Trends Biochem. Sci. 17, 315-320. 
[9] Sorgato, M.C. and Moran, O. (1993) Crit. Rev. Biochem. Mol. 
Biol. 18, 127-171. 
[10] Benz, R. (1994) Biochim. Biophys. Acta 1197, 167 196. 
[11] Colombini, M. (1994) Curr. Topics Membr. 42, 73-101. 
[12] K6nig, U., G6tz, H., Walter, G., Babel, D., Hohmeier, H.-E., 
Thinnes, F.P. and Hilschmann, N. (1991) Biol. Chem. Hoppe- 
Seyler 372, 565-572. 
[13] Cole, T., Awni, L.A., Nyakatura, E., G6tz, H., Walter, G., Thin- 
nes, F.P. and Hilschmann, N. (1992) Biol. Chem. Hoppe-Seyler 
373, 891-896. 
[14] Janisch, U., Skofitseh, G., Thinnes, F.P., Graier, W.F. and 
Groschner, K. (1993) Naunyn-Schmiedeberger's Arch. Pharma- 
col. Suppl. 347, R73. 
[15] Puchelle, E., Jacquot, J., Fuchey, C., Burlet, H., Klossek, J.M., 
Gilain, L., Triglia, J.M., Thinnes, F.P. and Hilschmann, N. (1993) 
Biol. Chem. Hoppe-Seyler 374, 297 304. 
[16] Dermietzel, R., Hwang, T.-K., Buettner, R., Hofer, A., Dotzler, 
E., Kremer, M., Deutzmann, R., Thinnes, F.P., Fishman, G.I., 
Spray, D.C. and Siemen, D. (1994) Proc. Natl. Acad. Sci. USA 91, 
499-503. 
[17] Junankar, ER., Curtis, S.M., Pace, S.M. and Dulhunty, A.F. 
(1993) Proc. Aust. Physiol. Pharmacol. Soc. 24, 179 p. 
[18] Bureau, M.H., Khrestchatisky, M., Heeren, M.A., Zambronicz, 
E.B., Kim, H., Grisar, T.M., Colombini, M., Tobin, A.J. and 
Olsen, R.W. (1992) J. Biol. Chem. 267, 8679-8684. 
[19] Lisanti, M.E, Scherer, EE., Vidugiriene, J., Tang, Z.L., Herma- 
nowski-Vosatka, A., Tu, Y.-H., Cook, R.F. and Sargiacomo, M. 
(1994) J. Cell Biol. 126, 111-126. 
[20] Thinnes, F.P. (1992) J. Bioenerg. Biomembr. 24, 71 75. 
[21] Reymann, S., F16rke, H., Heiden, M., Jakob, C., Stadtmiiller, U., 
Steinacker, E, Lalk, V.E., Pardowitz, I. and Thinnes, F.P. (1995) 
Biochem. Mol. Med. 54, 75-87. 
[22] Cole, S.R., Ashman, L.H. and Ey, EL. (1987) Mol. Immunol. 24, 
699-705. 
[23] Hurley, W.L., Finkelstein, E. and Holst, B.D. (1985) J. Immunol. 
Methods 85, 195-202. 
[24] Staros, J.V. (1982) Biochemistry 21, 3950-3955. 
[25] Anjaneyulu, P.S.R. and Staros, J.V. (1987) Int. J. Pept. Prot. Res. 
30, 117-124. 
[26] O'Farrell, EH. (1975) J. Biol. Chem. 250, 4007~,021. 
[27] O'Farrell, P.Z., Goodmann, H.M. and O'Farrell, P.H. (1977) Cell 
12, 1133-1142. 
[28] Linden, M., Gellerfors, P. and Dean Nelson, B. (1982) Biochem. 
J. 208, 77-82. 
